CDK2-IN-19

CDK2-IN-19

• UNSPSC Description: CDK2-IN-19 (Compound 32) is a selective and orally active CDK2 inhibitor (Ki: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors[1].
• Target Antigen: CDK
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/cdk2-in-19.html
• Solubility: 10 mM in DMSO
• Smiles: FC(C=C(S(=O)(NC)=O)C=C1)=C1NC2=NC=C3C(N=C(C(N4C[C@@H](OC)[C@@H]4C)=O)C=C3)=N2.FC(C=C(S(=O)(NC)=O)C=C5)=C5NC6=NC=C7C(N=C(C(N8C[C@H](OC)[C@H]8C)=O)C=C7)=N6
• Molecular Weight: 460.48
• References & Citations: [1]Mingshuo Zeng, et al. Discovery of Selective Tertiary Amide Inhibitors of Cyclin-Dependent Kinase 2 (CDK2). ACS Med. Chem. Lett. 2023.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported